In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in ...

In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene therapy ...

Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in ...

Feb 19 (Reuters) - Regeneron (REGN.O), opens new tab has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal kickbacks through a charity ...

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.

Celularity has entered into a multiyear Research Collaboration Services Agreement with Regeneron Pharmaceuticals. The initial focus of the agreement, announced Aug. 29, is research on a targeted ...

Regeneron and Bluebird have a prior cell therapy relationship. In 2018, the two companies struck a deal to apply their respective technologies toward the discovery of new cell therapies for cancer.